1. Covering the Cover Gastroenterology
Anson W. Lowe, Richard H. Moseley 
Gastroenterology 
Volume 148, Issue 4, Pages (April 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Percentage of patients who achieved the primary end point of remission at the end of 6 weeks.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
(A) Mean ± SD ALP relative change from baseline to end of study in the mITT (last observation carried forward) population. P < pair-wise comparison for all treatment groups. (B) Percent decrease in ALP values in the completer population. Pairwise comparisons for 10%, 20% and 40% cutoff, respectively: 10 mg P < .0001, P < .0001, P = .0031; 25 mg P < .0001, P < .0001, P = .0272; 50 mg P < .000l for all cutoffs, respectively. P value: Comparison of proportion of patients with a 10%, 20%, 40%, or complete response for OCA dose groups with placebo group using the likelihood ratio χ2 test. ∗∗P < .05; ∗∗∗P <
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

4. Figure 3
Lower numbers of HuC/D enteric neurons after treatment of zebrafish embryos with RAD21 morpholinos.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

5. Figure 4
Gene expression–based prognostic signature and its validation. (A–C) Kaplan–Meier plots estimating (A) overall survival in training (n = 29, left panel) and in the (C) validation French cohort (n = 22), and the (B) overall recurrence in those patients from the training set for whom data on recurrence were available (n = 26). (A) Heat-map shows expression values of the 8 genes that constitute the prognostic signature (right panel). Patients in the poor prognosis class (red) showed shorter survival times and earlier recurrences.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions